News of Note—Catalent upgrades Italy plant; Lonza adding ADC capacity

Microphone
(Pixabay)

> Catalent is investing $7.3 million at its Aprilia, Italy, facility to upgrade and expand its packaging and softgel encapsulation capabilities to 23 lines. Release

> CDMO Lonza says it will add two new manufacturing suites at its Visp, Switzerland, site to increase its capacity to manufacture antibody drug conjugate payloads. Release

> After investing €40 million to prepare for serialization to allow for the tracking of products, CDMO Recipharm says it has released its first serialized products to Europe from its facilities in Lisbon, Portugal, and Stockholm, Sweden. Release

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.